Clinical Update 2025: Recommendations on the Use of Antidepressants in Women Taking Tamoxifen
While some antidepressants may affect the metabolism of tamoxifen into its active form, many antidepressants can be used safely in this population.
While some antidepressants may affect the metabolism of tamoxifen into its active form, many antidepressants can be used safely in this population.
The recent FDA expert panel focused largely on the risks of SSRIs during pregnancy; Dr. Freeman weighs in on the information provided in the report.
While we have adequate data to support the use of SSRI and SNRI antidepressants during pregnancy, there is less data regarding other classes of antidepressants. Although we less commonly use mirtazapine in pregnancy, several [...]
Maternal SSRI use during pregnancy may be associated with altered brain development in children; however, this study cannot fully rule out contributions of confounding genetic and enviromental factors.
Maternal depression during the third trimester, not prenatal SSRI exposure, was associated with higher levels of internalizing and anxiety behaviors in children from 3 to 12 years of age.
All of our information on the reproductive safety of medications comes from non-randomized studies. However, many of these studies fail to take into consideration other factors associated with maternal psychiatric illness which may also affect outcomes.
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
Many women experience depression during pregnancy. What is the best way to identify these women?
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on clinical issues regarding prescribing antidepressants during pregnancy with Ob.Gyn News on March 23, [...]
Some studies have demonstrated associations between in utero exposure to antidepressants and cognitive outcomes.